Are corticosteroids safe for use during pregnancy?

Are Steroids Safe During Pregnancy?

Corticosteroids are safe for use during pregnancy when clinically indicated, with prednisone, prednisolone, and hydrocortisone being the preferred agents because they undergo extensive placental metabolism, limiting fetal exposure to approximately 10% of the maternal dose. 1, 2

Route-Specific Safety Profile

Topical/Intranasal Corticosteroids

• All modern intranasal corticosteroids (budesonide, fluticasone propionate, fluticasone furoate, mometasone) are safe at recommended doses throughout pregnancy. 1, 2
• Topical corticosteroids of any potency are not associated with birth defects, preterm delivery, fetal death, or low Apgar scores. 3
• However, potent to very potent topical corticosteroids in high cumulative doses are associated with fetal growth restriction (adjusted relative risk 2.08) and low birth weight. 4
• Intranasal corticosteroids carry no increased risk of major malformations, preterm delivery, low birth weight, or pregnancy-induced hypertension. 5, 6

Inhaled Corticosteroids

• Inhaled corticosteroids, including budesonide, are not associated with increased risk of major congenital malformations, intrauterine growth restriction, preterm delivery, or low birth weight at usual therapeutic doses. 2, 7
• Budesonide is the preferred inhaled corticosteroid during pregnancy due to the most extensive safety data. 7
• High-dose inhaled corticosteroids (>1000 µg/day) may carry a small increased risk of congenital anomalies, emphasizing the importance of using the minimum effective dose. 7, 8

Systemic Corticosteroids

Agent Selection

• Prednisone, prednisolone, and hydrocortisone are the only recommended systemic corticosteroids for maternal disease control. 1, 2
• Dexamethasone and betamethasone cross the placenta readily and must be reserved exclusively for fetal indications (lung maturation), never for maternal conditions. 1, 2

Safety Evidence

• First-trimester prednisone use for disease control is not associated with increased risk of major birth defects, stillbirth, preterm delivery, or congenital malformations according to large nationwide cohort data (≈52,000 pregnancies). 2
• Hydrocortisone is FDA pregnancy category B and has not demonstrated teratogenicity at therapeutic doses in humans. 2, 9

Dose-Related Risks

• Doses ≤5 mg/day prednisone are associated with low risk and should be the target maintenance dose. 1, 2
• Doses >5 mg/day are linked to dose-dependent adverse outcomes including gestational diabetes, pregnancy-associated osteoporosis, serious infections, preterm birth, preeclampsia, and low birth weight infants. 1, 2
• First-trimester use carries the greatest theoretical risk of teratogenicity, though large cohort data have not confirmed increased malformation rates. 1, 2

Dosing Algorithm

Initial Management

• Start with 10–20 mg/day prednisone for maternal disease control, then taper to the lowest effective dose, ideally ≤5 mg/day once stability is achieved. 2
• If doses >10 mg/day are required, strongly consider adding pregnancy-compatible glucocorticoid-sparing agents (azathioprine, hydroxychloroquine, cyclosporine, tacrolimus) to enable dose reduction. 1, 2
• Doses >20 mg/day should be tapered below this threshold, adding steroid-sparing agents as needed. 1, 2

Timing Considerations

• After the first trimester, short bursts of corticosteroids may be employed more liberally when maternal disease poses greater risk than medication. 1, 2
• Avoid aggressive tapering in the final weeks before delivery, as rapid dose reduction can precipitate disease flares. 2

Mandatory Monitoring

• Screen for gestational diabetes in all women receiving glucocorticoids due to hyperglycemic effects. 1, 2
• Monitor blood pressure closely for hypertension and preeclampsia. 2
• Assess weight gain, steroid-induced psychosis, and osteoporosis risk at routine follow-up. 2

Peripartum Stress-Dose Coverage

• Women on oral steroids ≥7.5 mg/day for ≥2 weeks require intravenous stress-dose hydrocortisone during active labor or cesarean section to prevent adrenal crisis. 2, 9
• Recommended regimen: 100 mg IV hydrocortisone at onset of active labor, followed by either continuous infusion of 200 mg/24 hours or 50 mg IM every 6 hours. 2, 9
• After uncomplicated delivery, rapidly taper over 1–3 days to the regular replacement dose. 2, 9

Breastfeeding Compatibility

• Prednisone and hydrocortisone are compatible with breastfeeding; low-dose therapy results in minimal drug transfer into milk. 1, 2, 9
• For prolonged high-dose maternal therapy, delaying breastfeeding by 3–4 hours after the dose reduces infant exposure. 2, 9

Critical Pitfalls to Avoid

• Never withhold necessary prednisone therapy due to pregnancy concerns—uncontrolled maternal disease poses greater risk to both mother and fetus than the medication. 2
• Do not confuse prednisone with mycophenolic acid products, which are absolutely contraindicated in pregnancy due to high malformation risk. 2
• Do not use dexamethasone or betamethasone for maternal conditions; these agents are intended only for fetal treatment. 1, 2
• Consult with the patient's obstetrician when prescribing systemic corticosteroids, especially for conditions less severe than life-threatening disease. 1, 2
• If high-dose prednisone is continued up to delivery, monitor the newborn for adrenal insufficiency. 2
• Do not forget stress-dose coverage during labor and delivery in patients on chronic corticosteroid therapy, as this can precipitate adrenal crisis. 9

When Corticosteroids Are Insufficient

• Consider intravenous immunoglobulin (IVIg) as an alternative when prednisone is ineffective or causes significant adverse effects. 2
• For severe, refractory, or organ/life-threatening maternal disease, options include IV methylprednisolone pulses, pregnancy-compatible immunosuppressants, or (in second/third trimester only) cyclophosphamide or mycophenolate. 1